Home Administrative Billing & Reimbursement BlueCard® Health and Wellness Medical PEAR portal Pharmacy Products Quality Management

Now in effect: Changes to precertification requirements for intravitreal VEGF products effective January 1, 2020

January 2, 2020

As previously communicated in a Partners in Health UpdateSM article, as of January 1, 2020,Avastin® and its biosimilars (i.e., Mvasi™, Zirabev™) are the preferred intravitreal vascular endothelial growth factor (VEGF) products for Independence commercial and Medicare Advantage members.* We will continue to cover the other intravitreal VEGF products, but they will be approved only for members who have demonstrated failure, contraindication, or intolerance to Avastin or an Avastin biosimilar.

Currently, there are six intravitreal VEGF products that treat ophthalmologic conditions such as neovascular (wet or exudative) advanced macular degeneration, and diabetic macular edema:

  • Avastin® (bevacizumab)
  • Eylea® (aflibercept)
  • Lucentis® (ranibizumab)
  • Macugen® (pegaptanib)
  • Mvasi™ (bevacizumab-awwb)
  • Zirabev™ (bevacizumab-bvzr)

Updates to VEGF precertification requirements for ophthalmologic indications

Requests for intravitreal Avastin or its biosimilars do not requireprecertification approval from Independence.

All new requests for Eylea, Lucentis, or Macugen received on or after January 1, 2020, require precertification approval for all Independence members.

Members who have received Eylea, Lucentis, or Macugen in the past 12 months will continue to be approved to receive treatment with these drugs.

Learn more

The following commercial and Medicare Advantage medical policies have been updated to reflect the new step therapy criteria:

  • Commercial: #08.00.74m: Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists and related biosimilars
  • Medicare Advantage: #MA08.073f: Intravitreal Injection of Vascular Endothelial Growth Factor (VEGF) Antagonists and related biosimilars

These changes are reflected in an updated precertification requirement list, which is posted on our website.

*As additional biosimilars to Avastin receive approval from the U.S. Food and Drug Administration, these products will also be designated as preferred products for Independence members.


This content was prepared for the Provider News Center and may not be reproduced in any way without the express written permission of Independence Blue Cross. Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association.
Connect with us     Facebook     Twitter     Flickr     YouTube     Walk the Talk    Independence Pinterest    Independence LinkedIn    Independence Instagram Site Map        Anti-Fraud        Privacy Policy        Legal        Disclaimer
© 2023 Independence Blue Cross.
Independence Blue Cross is an independent licensee of the Blue Cross and Blue Shield Association, serving the health insurance needs of Philadelphia and southeastern Pennsylvania.